Trial Profile
Assessment of the frequency of emergence, as defined by the presence of the H275Y mutation during oseltamivir therapy in inuenza A.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2017
Price :
$35
*
At a glance
- Drugs Oseltamivir (Primary)
- Indications Influenza A virus infections
- Focus Pharmacodynamics
- 30 Jun 2017 New trial record
- 05 Jun 2017 Results presented at the ASM Microbe 2017